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Overall Survival and Functional Results of 
Prostate-Sparing Cystectomy
A Matched Case-Control Study
Abbas Basiri,1 Hamid Pakmanesh,1 Ali Tabibi,1 Mohammad Hadi Radfar,1 Farzam Tajalli,1
Babak Ahadi,1 Nazanin Eslami2
Purpose: To compare two matched groups of men with bladder transitional cell carcinoma 
(TCC) who underwent prostate-sparing cystectomy (PSC) or conventional radical cystopros-
tatectomy (CRC).
Materials and Methods: Twenty-three men who have undergone PSC with the diagnosis of 
EODGGHU7&&7D±7IURPWRLQ7HKUDQ,UDQZHUHLQFOXGHGLQWKHVWXG\DVWKHH[-
perimental group. The control group composed of 27 men with comparable tumor character-
istics and age range, who had non-nerve-sparing radical cystoprostatectomy and orthotopic 
ileal W pouch reconstruction in the same center. All the procedures were performed by the 
same surgical group under the supervision of different attending staff.
Results: Mean follow-up period was 39 months in PSC and 35 months in CRC group. The 
5-year overall survival was 47% and 30% in PSC and CRC groups, respectively. Median 
survival was 48 months in PSC and 36 months in CRC group, using Kaplan-Meier survival 
analysis (P > .05). Impotence was observed in 16.6% in PSC and in 83.3% in CRC group 
(P  0HDQ ,QWHUQDWLRQDO ,QGH[RI(UHFWLOH)XQFWLRQ VFRUHRI WKH36&JURXSZDV
19.8 compared with 5.7 in the CRC group (P = .003). Only one patient in each group was 
completely incontinent. Urethral anastomosis stricture occurred in 2 patients in CRC group.
Conclusion: Patients who underwent PSC did not show decreased overall survival compared 
to CRC, which provided better functional results. 
Keywords: urinary bladder neoplasms, transitional cell carcinoma, cystectomy, male, prog-
nosis, adverse effects 
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INTRODUCTION
F
ormerly, radical cystoprostatectomy and urethrecto-
my were proposed for all men with bladder transition-
al cell carcinoma (TCC) indicated for cystectomy.(1,2)
But to achieve better functional results with acceptable tumor 
control, conventional radical cystoprostatectomy (CRC) and 
orthotopic reconstruction are usually performed for invasive 
bladder cancer. However, this radical surgery potentially car-
ries important inherent functional consequences that affect 
quality of life, especially in younger patients.
7KH FRQFHUQ DERXW ORVV RI VH[XDO IXQFWLRQ LV RQH RI WKH
PDLQFDXVHVRIGHOD\LQGH¿QLWLYHVXUJHU\LQPHQGLDJQRVHG
with muscle-invasive bladder tumor; the delay imposes an 
increased mortality rate.(3) This encourages some surgeons 
perform prostate-sparing cystectomy (PSC), which has better 
VH[XDO IXQFWLRQ UHVXOWV(4-6) In 1990s, Schilling and Friesen 
described transprostatic cystectomy to preserve the neuro-
YDVFXODUEXQGOHVDQGH[WHUQDOVSKLQFWHUDQGLPSURYHWKHSR-
tency results.(4) Although there is serious concern about the 
recurrence of TCC in the prostate,(6-8) some factors have been 
proposed which can help determine patients at high risk for 
the prostate involvement with TCC.(9) On the other hand, the 
incidence of incidental prostate adenocarcinoma has been 
shown to be low in a group of selected Iranian men who un-
derwent CRC for the bladder TCC.(10) This study aimed to 
compare two matched groups of Iranian men with bladder 
TCC who underwent CRC or PSC, in terms of functional and 
tumor control results with especial focus on survival. 
MATERIALS AND METHODS
Indication for radical cystectomy was a history of muscle-
invasive, recurrent, or unresectable bladder TCC. All the 
SDWLHQWVKDGSUHRSHUDWLYHF\VWRVFRS\DQGELPDQXDOH[DPL-
nation. Patients with TCC involvement of the prostatic ure-
thra or bladder neck on the pre-operative cystoscopy or any 
HYLGHQFHRIWKHFDUFLQRPDLQVLWX&,6ZHUHH[FOXGHGIURP
the study.
6HUXP OHYHO RI SURVWDWHVSHFL¿F DQWLJHQ 36$ DQG GLJLWDO
UHFWDOH[DPLQDWLRQZHUHQRUPDOLQDOOWKHSDWLHQWV5HJDUGLQJ
the low incidence of incidental prostate adenocarcinoma in 
Iran,(10) pre-operative prostate biopsy was not performed in 
this study. On pre-operative imaging studies, including ab-
dominopelvic spiral computed tomography (CT) scan with 
intravenous and oral contrast, all the patients had organ-con-
¿QHGEODGGHUWXPRUXQUHVHFWDEOHRUUHFXUUHQW7D7RU7
Data of pre-operative renal function and kidney ultrasonic 
H[DPLQDWLRQZHUHDOVRFROOHFWHG
Cystectomy was done through a lower midline incision or 
laparoscopically. Prostate adenoma was enucleated in conti-
nuity with the bladder specimen while urethral catheter was 
in place to prevent urine spillage. Intra-operative frozen sec-
tion of distal surgical margin was negative in all the patients. 
In the intra-operative observations, no lymphadenopathy 
was detected. An orthotopic ileal W neobladder was recon-
structed for all the patients. Pathological results of surgical 
specimens were collected.
Patients were followed up with abdominopelvic CT scan, 
chest radiography, liver function tests, and serum level of 
PSA. If there was a higher serum level of alkaline phos-
phatase or calcium, radionuclide whole body bone scan was 
performed. None of the patients underwent pre-operative 
radiotherapy or neoadjuvant chemotherapy, but adjuvant 
chemotherapy was given to patients with pathological stage 
RI7RU7LQWKH¿QDOSDWKRORJ\UHSRUW
All the patients were questioned about their continence and 
VH[XDOIXQFWLRQVWDWXVE\DSK\VLFLDQDWOHDVWVL[PRQWKVDI-
ter the operation. Potency status was evaluated before and 
after the surgical procedure using a simple presented scale 
DQG DOVR ,QWHUQDWLRQDO ,QGH[ RI (UHFWLOH )XQFWLRQ ,,()
5) questionnaire. Patients who used any pad during the day 
were marked as incontinent. 
Statistical Analysis
All the data were analyzed by SPSS software (the Statistical 
Package for the Social Sciences, Version 16.0, SPSS Inc, Chi-
cago, Illinois, USA). Data were presented as mean ± standard 
GHYLDWLRQ6'RUSHUFHQWDJH7KHVLJQL¿FDQFHRIGLIIHUHQFHV
between two groups was analyzed using Chi-Square test for 
categorical variables and independent sample t test for nu-
PHULFDOYDULDEOHV'LIIHUHQFHVZHUHFRQVLGHUHGVLJQL¿FDQWLI
P value was less than .05. Kaplan-Meier estimate of survival 
was used for survival analysis. 
RESULTS
A total of 50 patients, 23 in PSC group and 27 in CRC group, 
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ZHUHLQFOXGHGLQWKHDQDO\VLV7KHUHZDVQRVLJQL¿FDQWGLI-
ference between two groups in terms of age, pre-operative 
serum level of creatinine, presence of hydronephrosis, or tu-
mor stage and grade on transurethral resection of the prostate 
(TURP) (P > .05; Table 1).
5HVXOWVRISDWKRORJLFDOH[DPLQDWLRQRIWKHF\VWHFWRP\VSHFL-
men in two groups are presented in Table 2. The pathologi-
FDOVWDJHDQGJUDGHZHUHQRWVLJQL¿FDQWO\GLIIHUHQWEHWZHHQ
WZRJURXSV,QWKH¿QDOSDWKRORJ\RIWKHSURVWDWHLQWKH&5&
group, 2 cases of the adenocarcinoma with Gleason score of 
6 and 3 were detected. While in the PSC group, one patient 
with adenocarcinoma with Gleason score of 5 was detected 
in the enucleated prostate adenoma. They underwent watch-
IXOZDLWLQJDQGH[SHULHQFHGQRUHFXUUHQFHDWWKHHQGRIWKH
study. Only one patient in CRC group showed prostate stro-
mal involvement with TCC, who was a 65-year-old man with 
history of a high-grade bladder tumor and pre-operative bi-
lateral hydronephrosis. He was alive at 4-year follow-up with 
D ORFDO UHFXUUHQFH7KHUHZDVQRUHSRUWRI&,6 LQ WKH¿QDO
cystectomy specimen.
Mean follow-up period was 39 months in PSC group and 35 
months in CRC group (P = .65). Mean follow-up for patients 
who were alive in the last follow-up was 53 months (range, 
23 to 90 months) and 57 months (range, 17 to 110 months) 
in PSC and CRC groups, respectively. Mean survival time 
in the PSC and CRC groups was 27 months (range, 2 to 74 
months) and 22 months (range, 1 to 52 months), respectively. 
Twenty-nine (58%) patients, including 12 (52%) patients in 
the PSC group and 17 (63%) in the CRC group, died dur-
ing follow-up (P = .39). In 25 patients, the death cause was 
apparent; 22 deaths were caused by tumor or chemotherapy 
complications and 3 were due to myocardial infarction. 
The overall 5-year survival was 47% and 30% in PSC and 
CRC groups, respectively. Median overall survival was esti-
mated to be 48 months in PSC and 36 months in CRC group, 
using Kaplan-Meier survival analysis (P > .05; Figure). Two-
\HDURYHUDOOVXUYLYDOGLYLGHGE\VWDJHZDVQRWVLJQL¿FDQWO\
different between two groups (55% versus 52%; Table 3). 
The 5-year disease-free survival was estimated to be 35% in 
PSC and 13% in CRC group. 
Table 1. Pre-operative characteristics of patients in two groups.*§
Variable Radical cystoprostatectomy Prostate-sparing cystectomy P
Age, y 61 ± 12.0 59 ± 14.0 .59
Serum creatinine, mg/dL 1.2 ± 0.4 1 ± 0.3 .25
Hydronephrosis, n (%)
   No 11 (47.8) 11 (64.7)
   Yes 12 (52.5) 6 (35.3) .28
TURP stage, n (%)
   Recurrent Ta 1 (4.5) 0 (0.0)
   Recurrent T1 4 (18.2) 2 (10.5)
   T2 16 (72.5) 13 (68.4)
   Unresectable£ 1 (4.5) 4 (21.1) .31
TURP grade, n (%)
   I 4 (20) 1 (7.7)
   II 5 (25) 3 (23.1)
   III 11 (55) 9 (69.2) .58
*Data are presented as mean ± standard deviation or count (column percent). Percents were calculated excluding missing data.
§TURP indicates transurethral resection of the prostate.
£Tumor was not resectable via TURP, thus the real stage could not be evaluated.
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The recurrence data were available for 38 patients, including 
18 patients in PSC and 20 patients in CRC group. Twenty-
two (57.9%) patients developed tumor recurrence at follow-
up (61.1% in PSC and 55% in CRC group; P > .05). 
Twenty-four patients, including 12 patients in each group 
who were completely potent and able to have intercourse pre-
Table 2. Results of pathological evaluation of cystectomy specimen in two groups.*§
Variable Radical cystoprostatectomy Prostate-sparing cystectomy P
Tumor stage,£ n (%)
       T0 0 (0.0) 1 (4.3)
       T1                  6 (22.2) 7 (30.4) .51
       T2a   6 (22.2) 5 (21.7)
       T2b   6 (22.2) 4 (17.4)
       T3a 2 (7.4) 4 (17.4)
       T3b 5 (18.5) 2 (8.7)
       T4   2 (7.4) 0 (0.0)
Tumor grade, n (%)
       I   4 (14.8) 1 (5.3)
       II 5 (18.5) 3 (15.8) .54
       III   18 (66.7) 15 (78.9)
Prostate, n (%)
       Normal 18 (78.3) 12 (85.7)
       PI-TCC 1 (4.3) 0 (0.0)
       Adenocarcinoma 2 (8.7) 1 (7.1) .86
       HGPIN 2 (8.7) 1 (7.1)
*Percents were calculated excluding missing data.
§ PI-TCC indicates prostate involvement with transitional cell carcinoma; and HGPIN, high-grade prostate intra-epithelial neoplasia.
£Tumor stage was based on TNM tumor staging system; Sobin, L. H. and I. D. Fleming:"TNM Classification of Malignant Tumors, fifth 
edition (1997)". 
Table 3. Two-year survival data divided by final pathological 
stage.
Prostate-sparing 
cystectomy
Radical 
cystoprostatectomy
Stage no. 2-year survival no. 2-year survival
T1  7 53%  6 67%
T2  9 71% 12 55%
T3  6 33%  7 29%
All patients* 23 55% 27 52%
*Including one patient with stage T0 and two with T4.
Kaplan-Meier survival rate plot by surgery type.
PSC indicates prostate-sparing cystectomy; and CRC, conven-
tional radical cystectomy.
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operatively (IIEF score >20), cooperated for potency status 
interview. Of twelve patients in the CRC group, 10 (83.3%) 
showed severe erectile dysfunction (no erection), but in the 
PSC group, only 2 (16.6%) patients had no erection (P = 
.002; Table 4). Regarding the IIEF-5 questionnaire results, 
mean score of the PSC group was 19.8 compared with 5.7 in 
the CRC group (P = .003).
Data regarding postoperative continence status were col-
lected in 29 patients (16 in PSC and 13 in CRC group). As 
Table 4 shows, only one patient in each group was complete-
ly incontinent. Eight (50%) patients in PSC and 7 (53.8%) 
patients in CRC group did not need to do clean intermittent 
catheterization (CIC) to become continent (P > .05). Bed 
wetting was seen more frequently in CRC group, but the dif-
IHUHQFHZDVQRWVLJQL¿FDQW,QFRQWUDVWGHSHQGHQFHRQ&,&
IRUWKHEODGGHUHPSW\LQJZDVOHVVLQ&5&JURXS$IWHUH[-
cluding patients with any evidence of local or urethral tumor 
recurrence, only 2 (15.3%) patients in CRC group showed 
stricture at the urethral anastomosis (P > .05).
DISCUSSION
Kaplan-Meier analysis has not shown lower overall and dis-
ease-free survival rates for the patients who underwent PSC 
in comparison with the CRC group. Overall 5-year survival 
rate of patients after radical cystectomy reportedly is 50% to 
66%.(11-14) In a research by Rozet and colleagues, this rate 
was 67% in 107 patients selected for PSC. They reported 
long-term follow-up period of the largest group of PSC pa-
tients, and compared the survival results of their cohort with 
the literature data on the 5-year survival after CRC. They 
concluded that the results were comparable and “prostate-
sparing cystectomy is an additional option for treating high-
Table 4. Functional results of available patients in two groups.
Variable Radical cystoprostatectomy Prostate-sparing cystectomy P
Potency, n (%)
  Impotent 10/12  (83.3) 2/12 (16.6) .002
  Potent 2/12  (16.6) 10/12 (83.3)
      Erection, no penetrationa 2/12 (16.6) 3/12 (25.0)
      Penetration, no ejaculationb 0/12 (0) 3/12 (25.0)
      Penetration and ejaculationc 0/12 (0) 4/12 (33.3)
Continence, n (%)
  Totally incontinent 1/13 (7.6) 1/16 (6.2) NS
  Continent but Bed wettingd 4/13 (30.7) 2/16 (12.5)
  Continent with CICe 1/13 (7.6) 5/16 (31.2)
  Continent, no CIC 7/13 (53.8) 8/16 (50.0)
Stricturef, n (%)
   No 11/13 (84.6) 16/16 (100) NS
   Yes 2/13 (15.3) 0/16 (0)
a There was erection, but not enough for intercourse.
b Strong enough erection and ability for penetration, but dry ejaculation.
c As b, also complete normal ejaculation.
d No pad and no CIC in the daytime, but only bed wetting.
e These patients were dependent on CIC. 
f Patients with any evidence of local or urethral tumor recurrence were excluded.
*CIC indicates clean intermittent catheterization.
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ly selected patients who want to be offered curative therapy 
with minimal side effects.”(15)
In a recently published study, de Vries and associates evalu-
ated the long-term survival of 63 men who underwent PSC. 
7KH\HDUGLVHDVHVSHFL¿FVXUYLYDOUDWHZDVFRPSDUHG
with 64% in the CRC group. They concluded that this pro-
cedure is safe and could be offered to selected patients.(16) 
In our study, the overall 5-year survival rate was 30% in the 
CRC group and 47% in the PSC group. The lower survival of 
our patients compared with the survival rate in the literature 
may be due to delayed diagnosis and treatment of the patients 
LQ RXU FRXQWU\ ,W VHHPVZKLOH36& UHVXOWV LQ VLJQL¿FDQWO\
better functional recovery in selected patients, the tumor con-
WURODQGVXUYLYDODUHQRWVLJQL¿FDQWO\GLIIHUHQW
In long-term follow-up (mean of 54 months) of 108 patients 
after PSC by Rozet and coworkers, they found only 6 pa-
WLHQWVZLWKSURVWDWHDGHQRFDUFLQRPDLQWKHLU¿QDOSDWKRORJ\
of TURP specimen, and 3 patients out of 102 during later 
follow-up. All of them had a Gleason score of 6 and were 
treated effectively by brachytherapy, high-intensity focused 
ultrasound, or androgen deprivation therapy. The authors 
concluded that concomitant prostate carcinoma does not have 
VLJQL¿FDQWHIIHFWRQVXUYLYDORIWKHVHSDWLHQWVLQFRQWUDVWZLWK
TCC.(15) Furthermore, the risk of prostate adenocarcinoma 
LVVLJQL¿FDQWO\GLIIHUHQWLQYDULRXVUDFHV(17) and the amount 
of this risk should be regarded while considering prostate-
sparing for the treatment of the bladder TCC. 
de Veries and colleagues showed an incidence of 18% for 
incidental prostate adenocarcinoma in cystoprostatectomy 
specimens. They reported two patients with adenocarcinoma 
out of 63 patients who had undergone PSC; one died due to 
TCC recurrence and the other was alive at 50-month follow-
up.(16) In our study, only one (4.3%) patient in the PSC group 
and 2 (7.4%) patients in the CRC group had prostate ade-
QRFDUFLQRPDRQ¿QDOSDWKRORJ\1RRQHVKRZHGD*OHDVRQ
grade of more than 3; all of them selected watchful waiting. 
One of them died due to the recurrence of bladder tumor and 
others were alive with no evidence of prostate adenocarci-
noma recurrence. Furthermore, none of other patients in PSC 
group was suspicious for the prostate cancer during the post-
operative follow-up. Our data show that in selected patients 
of Iranian population, prostate adenocarcinoma is not a sig-
QL¿FDQWIDFWRUDJDLQVW36&
It is accepted that PSC has better functional results than CRC.
(5,8,15,18,19)6LPLODUO\ZHREVHUYHGDQDSSDUHQWO\EHWWHUVH[XDO
function in patients in PSC group while continence results 
ZHUHQRWVLJQL¿FDQWO\GLIIHUHQW$OWKRXJKQRQVLJQL¿FDQWSD-
tients in PSC group showed lower rate of bed wetting than 
CRC group, while their need to CIC for the bladder emptying 
was a little more. Similarly, some authors have indicated that 
in spite of lower rate of bed wetting, overcontinence may be 
an imperfection for PSC.(7) We think this shortcoming is not 
VLJQL¿FDQW FRPSDUHG WR WKHPDMRU DGYDQWDJHVRI WKLV WHFK-
nique. Finally, urethral anastomosis stricture occurred in 2 
patients in CRC group without tumor recurrence. This com-
plication did not take place in PSC group, which may be due 
to a wider anastomosis with the neobladder, 
Limitations
Although the patients in the CRC group were matched by 
DJHVWDJHDQGRWKHUDYDLODEOHFOLQLFDOVWDJLQJ¿QGLQJVZH
are aware that it is a retrospective study and selection bias 
may be present. Furthermore, because some patients did not 
cooperate tensely in the follow-up, they died without a dis-
tinct diagnosis of the site of recurrence or functional status. 
However, the vast majority of missed follow-up for function-
al evaluation seems to be related to patients’ death due to the 
proven fatal nature of the disease and its low 5-year overall 
survival. Finally, it would be better to compare functional 
results of patients who had undergone PSC with a group of 
nerve-sparing conventional cystectomy patients.
CONCLUSION
When selected patients are included, patients who underwent 
PSC did not show decreased overall and disease-free survival 
rates compared to CRC. Tumor recurrence rate was not as-
sociated with the type of surgery. Potency results were sig-
QL¿FDQWO\EHWWHUDIWHU36& WKDQ&5&KRZHYHUFRQWLQHQFH
results were not different. A randomized clinical trial is 
needed to disclose the truth about the safety of this functional 
preserving modality. 
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